{"gene":"OVOL2","run_date":"2026-06-10T05:19:53","timeline":{"discoveries":[{"year":2009,"finding":"OVOL2 directly represses c-Myc and Notch1 transcription in keratinocytes, thereby suppressing transient proliferation and terminal differentiation, respectively. This was established by chromatin immunoprecipitation, luciferase reporter, and functional rescue assays.","method":"ChIP, luciferase reporter assay, functional rescue assay, siRNA knockdown in HaCaT cells","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — multiple orthogonal methods (ChIP, luciferase, rescue) in a single focused study establishing direct transcriptional repression","pmids":["19700410"],"is_preprint":false},{"year":2014,"finding":"OVOL2 acts as a transcriptional repressor that directly represses myriad EMT inducers in mammary epithelial cells. Its absence switches TGF-β response from growth arrest to EMT. Forced expression of the repressor isoform of OVOL2 reprograms metastatic breast cancer cells from mesenchymal to epithelial state.","method":"Conditional Ovol2 knockout mice, in vivo mammary morphogenesis assay, forced expression in cancer cells, molecular characterization of TGF-β response","journal":"Developmental cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo KO with defined phenotype plus in vitro forced expression rescue, multiple orthogonal experiments","pmids":["24735879"],"is_preprint":false},{"year":2013,"finding":"OVOL1 and OVOL2 induce mesenchymal-to-epithelial transition (MET) in human cancers via a regulatory feedback loop with EMT-inducing transcription factor ZEB1, and regulate mRNA splicing by inducing ESRP1. Expression of OVOL-TFs in mesenchymal prostate cancer cells attenuates metastatic potential in mouse tumor models.","method":"Overexpression in cancer cell lines, mouse prostate tumor models, expression analysis across 917 cancer cell lines","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — in vivo mouse model plus in vitro overexpression, single lab, multiple cancer models","pmids":["24124593"],"is_preprint":false},{"year":2015,"finding":"OVOL2 and ZEB1 form a mutual inhibitory circuit (double-negative feedback loop). Evidence for direct mutual inhibition was obtained experimentally; this circuit generates multiple intermediate EMT states and modulates bidirectional transitions between epithelial and mesenchymal states.","method":"Mathematical modeling integrated with experimental validation; measurement of Ovol2 and Zeb1 expression in intermediate cell states","journal":"PLoS computational biology","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — systems biology approach with experimental validation of mutual inhibition, single lab","pmids":["26554584"],"is_preprint":false},{"year":2015,"finding":"OVOL2 inhibits WNT signaling by binding TCF4 and β-catenin and facilitating recruitment of histone deacetylase 1 (HDAC1) to the TCF4–β-catenin complex, thereby inhibiting expression of WNT-regulated EMT genes (e.g., SLUG). The OVOL2-containing complex was purified by tandem affinity purification and confirmed by co-immunoprecipitation.","method":"Tandem affinity purification, co-immunoprecipitation, luciferase reporter assays, lentiviral overexpression, intestine-specific Ovol2 knockout mice, Apc(min/+) cross","journal":"Gastroenterology","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — complex purification by TAP/MS confirmed by Co-IP, reporter assays, and in vivo genetic models with defined phenotype","pmids":["26619963"],"is_preprint":false},{"year":2015,"finding":"Non-coding mutations in the OVOL2 proximal promoter cause autosomal-dominant corneal endothelial dystrophies CHED1 and PPCD1. All four mutated OVOL2 promoters showed increased transcriptional activity compared to wild-type in vitro, indicating gain-of-function aberrant OVOL2 expression in corneal endothelium as disease mechanism. OVOL2 is a direct transcriptional repressor of ZEB1.","method":"Targeted and whole-genome sequencing, direct promoter sequencing in pedigrees, in vitro luciferase transcriptional activity assays","journal":"American journal of human genetics","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — functional promoter assay replicated across four independent mutations, large pedigree-based genetic study with functional validation","pmids":["26749309"],"is_preprint":false},{"year":2006,"finding":"Ovol2 is required for cranial neural tube development, neural crest cell migration and survival, and proper ectodermal patterning in mice. Ovol2 knockout results in lethality by E10.5 with open cranial neural tube, improper Shh expression, and lateral shift of neuroectoderm/surface ectoderm border.","method":"Ovol2 gene knockout mice, in situ hybridization, immunostaining, marker expression analysis","journal":"Developmental biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — full KO mouse model with multiple defined molecular phenotypes, replicated by another KO study","pmids":["16423343"],"is_preprint":false},{"year":2007,"finding":"Ovol2 is required for extraembryonic and embryonic vascularization and heart formation in mice. Ovol2-deficient mice die at E9.5–10.5 due to vascular and cardiac defects. In an endothelial cell line, siRNA knockdown of Ovol2 inhibited capillary-like network formation on Matrigel.","method":"Gene-targeted Ovol2 knockout mice, siRNA knockdown in endothelial cells, Matrigel capillary formation assay","journal":"Genes to cells : devoted to molecular & cellular mechanisms","confidence":"High","confidence_rationale":"Tier 2 / Moderate — in vivo KO with defined vascular phenotype plus in vitro functional assay, single lab","pmids":["17573777"],"is_preprint":false},{"year":2006,"finding":"OVOL2 is a downstream target of OVOL1: Ovol1 represses Ovol2 promoter activity in a DNA binding-dependent manner, and Ovol2 expression is upregulated in Ovol1-deficient epidermis.","method":"Ovol1 knockout mouse analysis, promoter repression assay (DNA binding-dependent), qRT-PCR","journal":"Biochimica et biophysica acta","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — promoter assay plus in vivo mouse model, single lab","pmids":["17049212"],"is_preprint":false},{"year":2013,"finding":"Ovol2 acts downstream of the BMP signaling pathway: BMP4 directly regulates Ovol2 expression through binding of Smad1/5/8 to the second intron of the Ovol2 gene. Ovol2 in turn promotes mesendodermal and inhibits neural differentiation, mediating BMP-directed cell fate decisions between neuroectoderm and mesendoderm.","method":"ES cell differentiation assays, Ovol2 knockdown and overexpression, ChIP showing Smad1/5/8 binding to Ovol2 intron 2, chick embryo electroporation","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — ChIP demonstrating direct Smad binding plus functional rescue in ES cells and in vivo chick model, multiple orthogonal methods","pmids":["23319585"],"is_preprint":false},{"year":2014,"finding":"OVOL2 directly interacts with ER71/ETV2 transcription factor in the nucleus (but not with ETS1 or ETS2). This interaction enhances ER71-mediated activation of the Flk1 promoter and is critical for generation of FLK1+, endothelial, and hematopoietic cells from embryonic stem cells.","method":"Co-immunoprecipitation, luciferase reporter assay (Flk1 promoter), shRNA-mediated knockdown, ES cell differentiation assay","journal":"Blood","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — Co-IP plus functional reporter assay plus shRNA rescue in ES cell differentiation, single lab with multiple orthogonal methods","pmids":["25267199"],"is_preprint":false},{"year":2016,"finding":"OVOL2 directly represses Twist1 transcription in lung adenocarcinoma cells by binding to the Twist1 promoter, thereby suppressing EMT-associated migration and invasion.","method":"Luciferase reporter assay, chromatin immunoprecipitation (ChIP), Transwell and wound healing assays, rescue experiment","journal":"Gene","confidence":"Medium","confidence_rationale":"Tier 1–2 / Moderate — ChIP plus luciferase reporter confirming direct promoter binding, functional rescue, single lab","pmids":["27884772"],"is_preprint":false},{"year":2017,"finding":"OVOL2 inhibits TGF-β signaling at multiple levels: it inhibits Smad4 mRNA expression, induces Smad7 mRNA expression, blocks Smad4 binding to target DNA, and interferes with complex formation between Smad4 and Smad2/3, thereby antagonizing TGF-β-induced EMT in mammary tumor cells.","method":"Overexpression and knockdown in mammary tumor cell lines, RT-PCR, co-immunoprecipitation, in vivo mouse tumor models","journal":"Oncotarget","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — multiple mechanistic levels shown by Co-IP and gene expression assays, in vivo validation, single lab","pmids":["28455959"],"is_preprint":false},{"year":2018,"finding":"OVOL2 directly suppresses ZEB1 transcription in osteosarcoma cells by binding to the ZEB1 promoter, as demonstrated by luciferase reporter assay and ChIP.","method":"Luciferase reporter assay, ChIP, overexpression in MG-63 and SW1353 cells, immunohistochemistry in patient OS tissues","journal":"OncoTargets and therapy","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP plus reporter assay confirming direct promoter binding in two cell lines, single lab","pmids":["29872308"],"is_preprint":false},{"year":2018,"finding":"OVOL2 is PARylated by PARP1 at Lysine 145, Lysine 176, and Lysine 212 within its C2H2 zinc finger domains. PARylated OVOL2 alters cell morphology, induces lagging chromosomes and aneuploidy, elevates Cyclin E protein stability, and transcriptionally represses Skp2 (E3 ubiquitin ligase of Cyclin E), as mapped by ChIP.","method":"Proteomic approach to identify PARP1 substrate, site-specific mutagenesis (K145/176/212A), Co-IP, ChIP mapping of Skp2 promoter binding site, xenograft and MMTV-PyVT transgenic mouse models","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — proteomic identification plus site-directed mutagenesis plus ChIP plus in vivo mouse models, single lab with multiple orthogonal methods","pmids":["30542118"],"is_preprint":false},{"year":2018,"finding":"OVOL2 overexpression in fibroblasts suppresses fibroblast-associated gene loci (chromatin becomes inaccessible at OVOL2 target loci) and facilitates reprogramming into epithelial lineages cooperatively with KLF4 and TP63. OVOL2 acts as a transcriptional repressor of fibroblast identity genes.","method":"Overexpression in dermal fibroblasts, ATAC-seq (chromatin accessibility), motif enrichment analysis, co-expression with KLF4/TP63/HNF1A","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ATAC-seq plus functional reprogramming assay, single lab","pmids":["31019211"],"is_preprint":false},{"year":2018,"finding":"OVOL2 downregulation in bovine trophoblasts during implantation occurs via the TEAD3/YAP signaling pathway and results in upregulation of ZEB1, SNAI2, and mesenchymal markers. OVOL2 overexpression decreases ZEB1 transcripts and increases E-cadherin in trophoblast cells.","method":"Global expression analysis, trophoblast attachment co-culture system, OVOL2 overexpression and knockdown, RT-PCR, Western blot","journal":"FASEB journal","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — in vitro co-culture system with overexpression/knockdown, mechanistic pathway (TEAD3/YAP) identified, single lab","pmids":["29394105"],"is_preprint":false},{"year":2018,"finding":"Deletion of Ovol2 in mouse skin epithelium impairs directional migration (increased speed but reduced directionality) and proliferation of keratinocytes and bulge hair follicle stem cells. Simultaneous deletion of Zeb1 restores directional migration to Ovol2-deficient cells, placing Zeb1 downstream of Ovol2 in this process. Live imaging and genetic epistasis established these relationships.","method":"Conditional Ovol2 KO mice, Ovol2/Zeb1 double KO epistasis, live imaging of wound explants and Bu-HFSCs, wound healing and anagen assays","journal":"EMBO reports","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis with double KO, live imaging, defined cellular phenotypes, in vivo and in vitro convergent evidence","pmids":["30413481"],"is_preprint":false},{"year":2019,"finding":"OVOL2 overexpression (along with PAX6 and KLF4) directly reprograms human fibroblasts into corneal epithelial cell-like cells. Suppression of OVOL2 in corneal epithelial cells induces qualities consistent with neural lineage cells, indicating OVOL2 maintains corneal epithelial lineage identity.","method":"Transcription factor overexpression in human fibroblasts, loss-of-function (OVOL2 knockdown) in corneal epithelial cells","journal":"Cornea","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — overexpression and knockdown with defined cell-fate phenotype, single lab","pmids":["31403532"],"is_preprint":false},{"year":2020,"finding":"OVOL2 directly binds to and represses the ID2 gene locus in trophoblast stem cells, and directly represses ID2 transcriptional activity. OVOL2-driven repression of ID2 promotes TS cell differentiation; overexpression of ID2 alone is sufficient to reinforce the TS cell stem state.","method":"ChIP (OVOL2 binding proximal to ID2 gene), ectopic OVOL2 expression in TS cells, Ovol2 KO TS cells, ID2 overexpression rescue assay","journal":"Cells","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — ChIP demonstrating direct binding plus functional rescue (ID2 overexpression), KO and overexpression convergent evidence, single lab","pmids":["32244352"],"is_preprint":false},{"year":2021,"finding":"In pancreatic β-cells, Pdx1 transactivates Ovol2, which in turn represses Zeb2. Loss of Pdx1 reduces OVOL2 protein, triggering Zeb2-mediated mesenchymal reprogramming of β-cells. Loss- and gain-of-function experiments in MIN6 and EndoC-βH1 cell lines established this Pdx1/Ovol2/Zeb2 axis.","method":"Bulk and single-cell RNA-seq, loss- and gain-of-function in MIN6 and EndoC-βH1 cells, analysis of T2D mouse and human datasets","journal":"Molecular metabolism","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — RNA-seq plus loss/gain-of-function in two cell lines, supported by in vivo mouse data, single lab","pmids":["33989778"],"is_preprint":false},{"year":2022,"finding":"OVOL2 represses aerobic glycolysis in breast cancer by recruiting NCoR (nuclear receptor co-repressor) and HDAC3 to directly repress expression of glycolytic genes. The tumor suppressor p53 activates OVOL2 by binding MDM2 and inhibiting MDM2-mediated ubiquitination and degradation of OVOL2, establishing a p53/MDM2/OVOL2 axis.","method":"In vitro and in vivo overexpression/KO studies, Co-IP for NCoR/HDAC3 interaction, glycolysis assays, ubiquitination assay","journal":"Advanced science","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP identifying co-repressor complex plus ubiquitination assay, functional assays in vitro and in vivo, single lab","pmids":["35896951"],"is_preprint":false},{"year":2022,"finding":"OVOL2 directly binds P65 (NF-κB subunit) and inhibits recruitment of P300 while facilitating HDAC1 binding to P65, thereby suppressing NF-κB signaling and GLUT1 translocation/glucose import in NSCLC. Conversely, NF-κB signaling negatively regulates OVOL2 expression via the ubiquitin-proteasome pathway.","method":"Co-immunoprecipitation, luciferase assay, xenograft mouse models, Western blot, immunostaining","journal":"Cell communication and signaling","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP identifying direct P65 binding plus functional consequence on HDAC1/P300 recruitment, in vivo validation, single lab","pmids":["35346238"],"is_preprint":false},{"year":2022,"finding":"OVOL2 transcriptionally inhibits RhoU and RhoJ (RHO GTPase pathway members) in anaplastic thyroid cancer cells, causing G2/M cell cycle block, mitotic spindle abnormalities, and reduced invasiveness. Silencing of RhoU alone recapitulated the OVOL2-driven phenotype. OVOL2 new direct target genes were identified by RNA-seq and ChIP-seq.","method":"OVOL2 overexpression in ATC cell lines, RNA-seq, ChIP-seq, RhoU/RhoJ knockdown, cell cycle analysis, immunofluorescence of mitotic spindle","journal":"Journal of experimental & clinical cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP-seq plus RNA-seq plus rescue by RhoU silencing, single lab","pmids":["35337349"],"is_preprint":false},{"year":2022,"finding":"OVOL2 is required for thermogenesis in brown/beige adipose tissue and limits white adipogenesis. In white adipose tissue, OVOL2 inhibited adipogenesis by blocking C/EBPα engagement of its transcriptional targets. Identified via random germline mutagenesis (hypomorphic boh allele causing obesity).","method":"ENU-mutagenesis hypomorphic mouse allele (boh), pair-feeding experiments, Ovol2 overexpression in adipocytes, cold tolerance tests, Lepob/ob cross","journal":"Cell metabolism","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo hypomorphic allele with defined metabolic phenotype, overexpression rescue, genetic cross, multiple orthogonal in vivo experiments","pmids":["36228616"],"is_preprint":false},{"year":2022,"finding":"OVOL2 sustains postnatal thymic epithelial cell (TEC) identity by inhibiting the epigenetic regulatory BRAF-HDAC complex, specifically disrupting RCOR1-LSD1 interaction, which causes inhibition of LSD1-mediated H3K4me2 demethylation, resulting in chromatin accessibility and transcriptional activation of epithelial genes. A missense allele (C120Y) established this mechanism.","method":"Viable Ovol2 missense (C120Y) mouse allele, TEC-specific Cre deletion, Co-IP for BRAF-HDAC/RCOR1-LSD1 interaction, chromatin accessibility assays, H3K4me2 demethylation assays","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — Co-IP identifying complex disruption plus chromatin/epigenetic assays plus in vivo mouse model with defined phenotype, multiple orthogonal methods","pmids":["38012144"],"is_preprint":false},{"year":2022,"finding":"A viable hypomorphic Ovol2 allele in mice (boh) reveals that OVOL2 is required for normal energy expenditure. OVOL2-deficient mice develop obesity with normal food intake but decreased energy expenditure, extreme cold intolerance, and insulin resistance.","method":"Random germline mutagenesis, pair-feeding, metabolic cage analysis, body composition measurement","journal":"Cell metabolism","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo genetic model with multiple metabolic phenotypes, pair-feeding controls, replicated in Lepob/ob cross","pmids":["36228616"],"is_preprint":false},{"year":2024,"finding":"Loss of OVOL2 in triple-negative breast cancer promotes fatty acid oxidation (FAO) fueling stemness. Mechanistically, OVOL2 suppresses STAT3 phosphorylation by directly inhibiting JAK transcription and recruits HDAC1 to STAT3, reducing transcriptional activation of CPT1A and CPT1B (FAO rate-limiting enzymes).","method":"OVOL2 KO mice (PyVT-Ovol2 KO), Co-IP for HDAC1-STAT3 interaction, luciferase and ChIP for JAK promoter, FAO inhibitor treatment, sphere-forming assay","journal":"Advanced science","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP plus ChIP/luciferase identifying direct targets, in vivo KO mouse model, single lab","pmids":["38627980"],"is_preprint":false},{"year":2011,"finding":"Ovol2/MOVO protein localizes to the XY body in spermatocytes at the pachytene stage. In a reporter assay, Ovol2/MOVO repressed histone H1t promoter activity in a spermatogenic cell line, suggesting a role in XY body-associated gene repression during spermatogenesis.","method":"Immunohistochemistry with anti-Ovol2 antiserum in mouse testes, luciferase reporter assay (H1t promoter) in GC-2spd cells","journal":"Journal of andrology","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — direct localization by immunohistochemistry plus reporter assay in spermatogenic cell line, single lab","pmids":["21636736"],"is_preprint":false},{"year":2022,"finding":"Ovol2a splice variant (encoding repressor domain) directly regulates EMT-related genes and induces re-acquisition of pluripotency potential during primordial germ cell (PGC) specification, while Ovol2b splice variant (lacking the repressor domain) directly upregulates genes associated with PGC specification. These functions were established in mouse epiblast during gastrulation.","method":"Splice variant-specific knockout/knockin in mouse embryos, transcriptome analysis, direct gene target identification","journal":"Development (Cambridge, England)","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo splice-variant-specific KO/KI distinguishing isoform functions, single lab","pmids":["35029669"],"is_preprint":false},{"year":2021,"finding":"OVOL2 inhibits EMT in colorectal cancer cells by blocking the MAP3K8/AKT/NF-κB signaling pathway, identified by cross-referencing ChIP-seq data with RNA-seq differentially expressed genes in OVOL2-overexpressing vs. knockdown cells.","method":"RNA-seq, ChIP-seq (GSM1239518), wound-healing and Transwell assays, overexpression and knockdown in HCT116/SW480 cells","journal":"Pathology, research and practice","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP-seq plus RNA-seq cross-referencing plus functional assays, single lab","pmids":["34098198"],"is_preprint":false},{"year":2017,"finding":"In cutaneous squamous cell carcinoma, OVOL1 is an upstream suppressor of OVOL2 and c-Myc: knockdown of OVOL1 using siRNA increased mRNA and protein levels of both c-Myc and OVOL2. Knockdown of OVOL2 did not significantly affect c-Myc or OVOL1 levels.","method":"siRNA knockdown of OVOL1 and OVOL2 in A431 SCC cell line, RT-PCR, Western blot, immunohistochemistry in clinical samples","journal":"Modern pathology","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — siRNA knockdown experiments in one cell line with molecular readout, supported by IHC in clinical samples, single lab","pmids":["28339425"],"is_preprint":false}],"current_model":"OVOL2 is an evolutionarily conserved C2H2 zinc-finger transcriptional repressor that maintains epithelial identity by directly repressing EMT inducers (ZEB1, Twist1, Snail family members) and key cell-cycle/differentiation regulators (c-Myc, Notch1, ID2), operating downstream of BMP/Smad and Wnt/TCF4-β-catenin signaling; it forms direct protein complexes with co-repressors (HDAC1, HDAC3, NCoR) to suppress glycolysis, FAO, and NF-κB-driven glucose import, is subject to PARP1-mediated PARylation and MDM2-mediated ubiquitination that modulate its activity, and controls epithelial lineage identity in diverse tissues (mammary gland, thymus, placenta, adipose, cornea) through both transcriptional repression and epigenetic remodeling (disruption of RCOR1-LSD1-mediated H3K4me2 demethylation)."},"narrative":{"mechanistic_narrative":"OVOL2 is an evolutionarily conserved C2H2 zinc-finger transcriptional repressor that safeguards epithelial identity and governs developmental cell-fate decisions, principally by directly silencing EMT-inducing transcription factors [PMID:24735879, PMID:29872308]. Its central regulatory module is a double-negative feedback circuit with ZEB1: OVOL2 binds and represses the ZEB1 promoter, and the two factors mutually inhibit one another to generate stable epithelial, mesenchymal, and intermediate states [PMID:26554584, PMID:29872308]. Beyond ZEB1, OVOL2 directly represses Twist1, c-Myc, Notch1, and ID2, thereby restraining EMT, proliferation, terminal differentiation, and stemness across keratinocytes, lung and breast carcinoma, and trophoblast stem cells [PMID:19700410, PMID:27884772, PMID:32244352]. OVOL2 also antagonizes signaling inputs that drive mesenchymal programs: it binds the TCF4–β-catenin complex and recruits HDAC1 to block WNT-driven EMT genes, inhibits TGF-β/Smad signaling, and binds NF-κB p65 to favor HDAC1 over p300 recruitment [PMID:26619963, PMID:28455959, PMID:35346238]. It acts downstream of BMP/Smad and lineage factors such as Pdx1 to direct fate choices between neuroectoderm and mesendoderm and to maintain β-cell, corneal, and thymic epithelial identity [PMID:23319585, PMID:33989778, PMID:38012144]. OVOL2 is required in vivo for cranial neural tube closure, vascular and cardiac development, and epithelial morphogenesis, and its activity is tuned post-translationally by PARP1-mediated PARylation within its zinc-finger domains and by p53/MDM2-controlled ubiquitination [PMID:16423343, PMID:17573777, PMID:30542118, PMID:35896951]. Through co-repressor recruitment (HDAC1, HDAC3, NCoR) and disruption of RCOR1-LSD1-mediated H3K4me2 demethylation, OVOL2 enforces transcriptional and epigenetic repression that also restrains aerobic glycolysis and fatty-acid oxidation and supports adaptive thermogenesis [PMID:35896951, PMID:38012144, PMID:38627980, PMID:36228616]. In humans, non-coding gain-of-function mutations in the OVOL2 proximal promoter cause the autosomal-dominant corneal endothelial dystrophies CHED1 and PPCD1 [PMID:26749309].","teleology":[{"year":2006,"claim":"Established that OVOL2 is essential in vivo before any molecular targets were known, defining its developmental requirement in neural tube, ectodermal patterning, and vascular/cardiac formation.","evidence":"Ovol2 knockout mice with in situ hybridization and marker analysis; endothelial siRNA and Matrigel assay","pmids":["16423343","17573777"],"confidence":"High","gaps":["Direct transcriptional targets driving these phenotypes not yet identified","Did not establish whether defects are cell-autonomous"]},{"year":2006,"claim":"Placed OVOL2 within an OVOL regulatory hierarchy by showing OVOL1 represses the Ovol2 promoter in a DNA-binding-dependent manner.","evidence":"Ovol1 knockout epidermis analysis, promoter repression assay, qRT-PCR","pmids":["17049212"],"confidence":"Medium","gaps":["Single lab","Functional consequence of OVOL1→OVOL2 repression in vivo not resolved"]},{"year":2009,"claim":"Identified the first direct OVOL2 target genes (c-Myc, Notch1), establishing it as a sequence-specific transcriptional repressor coordinating proliferation and differentiation in keratinocytes.","evidence":"ChIP, luciferase reporter, and functional rescue with siRNA knockdown in HaCaT cells","pmids":["19700410"],"confidence":"High","gaps":["Co-repressor machinery not defined","Limited to keratinocyte context"]},{"year":2013,"claim":"Defined OVOL2 as a downstream effector of BMP/Smad signaling that biases neuroectoderm-versus-mesendoderm fate decisions.","evidence":"ES cell differentiation, ChIP of Smad1/5/8 at Ovol2 intron 2, chick embryo electroporation","pmids":["23319585"],"confidence":"High","gaps":["Downstream targets mediating mesendoderm induction not fully mapped"]},{"year":2013,"claim":"Generalized OVOL2 function to cancer by showing OVOL-TFs drive MET via a ZEB1 feedback loop and induce ESRP1-dependent splicing, attenuating metastasis.","evidence":"Overexpression in cancer lines, mouse prostate tumor models, expression survey across 917 lines","pmids":["24124593"],"confidence":"Medium","gaps":["Directness of ZEB1 feedback established later","Single lab"]},{"year":2014,"claim":"Demonstrated in vivo that OVOL2 loss converts the TGF-β response from growth arrest to EMT, and that the repressor isoform reprograms metastatic cells back to epithelial state.","evidence":"Conditional Ovol2 knockout mice, mammary morphogenesis, forced expression rescue in cancer cells","pmids":["24735879"],"confidence":"High","gaps":["Full repertoire of repressed EMT inducers not enumerated"]},{"year":2014,"claim":"Revealed an activating (non-repressive) mode of OVOL2 action through direct nuclear interaction with ER71/ETV2 to drive endothelial/hematopoietic specification.","evidence":"Co-IP, Flk1 promoter luciferase, shRNA knockdown in ES cell differentiation","pmids":["25267199"],"confidence":"High","gaps":["How OVOL2 switches between repressor and co-activator roles unknown"]},{"year":2015,"claim":"Mechanistically linked OVOL2 to WNT antagonism by showing it binds TCF4/β-catenin and recruits HDAC1 to repress WNT-EMT genes, with in vivo tumor relevance.","evidence":"Tandem affinity purification, Co-IP, luciferase, intestine-specific KO and Apc(min/+) cross","pmids":["26619963"],"confidence":"High","gaps":["Whether HDAC1 recruitment is universal across OVOL2 targets not established"]},{"year":2015,"claim":"Formalized the OVOL2–ZEB1 double-negative feedback loop as the bistable switch generating intermediate EMT states.","evidence":"Mathematical modeling with experimental measurement of Ovol2/Zeb1 in intermediate states","pmids":["26554584"],"confidence":"Medium","gaps":["Systems-level inference; in vivo proof of intermediate-state control limited"]},{"year":2015,"claim":"Connected OVOL2 to human disease, showing promoter mutations cause CHED1/PPCD1 via gain-of-function aberrant expression in corneal endothelium.","evidence":"Pedigree sequencing plus in vitro promoter luciferase activity across four mutations","pmids":["26749309"],"confidence":"High","gaps":["In vivo demonstration of corneal endothelial dysregulation by mutant promoters not shown"]},{"year":2016,"claim":"Extended the direct repressor target set to Twist1, broadening OVOL2's EMT-suppressive reach to lung adenocarcinoma.","evidence":"Luciferase, ChIP, Transwell/wound healing, rescue in lung cancer cells","pmids":["27884772"],"confidence":"Medium","gaps":["Single lab","In vivo confirmation absent"]},{"year":2017,"claim":"Showed OVOL2 antagonizes TGF-β at multiple nodes (Smad4 suppression, Smad7 induction, blocking Smad4 DNA binding and Smad2/3 complex formation).","evidence":"Overexpression/knockdown in mammary tumor cells, RT-PCR, Co-IP, in vivo tumor models","pmids":["28455959"],"confidence":"Medium","gaps":["Whether effects are direct vs. secondary to EMT reversal not fully separated"]},{"year":2017,"claim":"Reinforced the OVOL1→OVOL2/c-Myc hierarchy in squamous carcinoma, placing OVOL2 downstream of OVOL1.","evidence":"siRNA knockdown in A431 cells, RT-PCR, Western, IHC in clinical samples","pmids":["28339425"],"confidence":"Medium","gaps":["Single cell line","Directionality of OVOL2 effects on c-Myc not resolved here"]},{"year":2018,"claim":"Uncovered post-translational control: PARP1 PARylates OVOL2 within its zinc fingers, altering its repression of Skp2 and driving chromosomal instability.","evidence":"Proteomics, site-directed mutagenesis (K145/176/212A), Co-IP, ChIP, xenograft and MMTV-PyVT models","pmids":["30542118"],"confidence":"High","gaps":["Stimuli triggering PARylation in vivo not defined"]},{"year":2018,"claim":"Established OVOL2 as an epigenetic repressor of fibroblast identity capable of cooperating with KLF4/TP63 to reprogram cells toward epithelial lineages.","evidence":"Overexpression in dermal fibroblasts, ATAC-seq, motif enrichment","pmids":["31019211"],"confidence":"Medium","gaps":["Co-repressor mediating chromatin closure not identified in this study"]},{"year":2018,"claim":"Defined a ZEB1-dependent cellular mechanism: OVOL2 controls directional keratinocyte/stem-cell migration via repression of Zeb1, shown by genetic epistasis.","evidence":"Conditional and Ovol2/Zeb1 double KO mice, live imaging, wound-healing and anagen assays","pmids":["30413481"],"confidence":"High","gaps":["Molecular link between ZEB1 and directional cytoskeletal control not detailed"]},{"year":2018,"claim":"Implicated TEAD3/YAP-driven OVOL2 downregulation in trophoblast EMT during implantation, situating OVOL2 in placental epithelial control.","evidence":"Trophoblast co-culture, OVOL2 overexpression/knockdown, RT-PCR, Western","pmids":["29394105"],"confidence":"Medium","gaps":["Direct OVOL2 promoter occupancy at ZEB1/SNAI2 in trophoblast not shown"]},{"year":2019,"claim":"Showed OVOL2 maintains corneal epithelial lineage identity, with loss producing neural-like fate, and enabling fibroblast-to-corneal-epithelial reprogramming.","evidence":"TF overexpression in human fibroblasts and OVOL2 knockdown in corneal epithelial cells","pmids":["31403532"],"confidence":"Medium","gaps":["Direct target genes in cornea not mapped","Single lab"]},{"year":2020,"claim":"Identified ID2 as a direct OVOL2 target whose repression promotes trophoblast stem-cell differentiation.","evidence":"ChIP, ectopic OVOL2 and Ovol2 KO in TS cells, ID2 overexpression rescue","pmids":["32244352"],"confidence":"High","gaps":["Co-repressor recruitment at ID2 locus not characterized"]},{"year":2021,"claim":"Defined a Pdx1/Ovol2/Zeb2 axis preserving β-cell identity, where OVOL2 loss permits Zeb2-driven mesenchymal reprogramming relevant to diabetes.","evidence":"Bulk and scRNA-seq, loss/gain-of-function in MIN6 and EndoC-βH1, T2D datasets","pmids":["33989778"],"confidence":"Medium","gaps":["Direct OVOL2 binding at Zeb2 promoter not shown here","Single lab"]},{"year":2021,"claim":"Linked OVOL2 to MAP3K8/AKT/NF-κB suppression as a mechanism of EMT inhibition in colorectal cancer.","evidence":"RNA-seq and ChIP-seq cross-referencing, wound-healing/Transwell, overexpression/knockdown","pmids":["34098198"],"confidence":"Medium","gaps":["Direct vs. indirect regulation of MAP3K8 not fully resolved"]},{"year":2022,"claim":"Showed OVOL2 represses aerobic glycolysis via NCoR/HDAC3 recruitment, and is itself stabilized by p53 through inhibition of MDM2-mediated degradation.","evidence":"Overexpression/KO, Co-IP for NCoR/HDAC3, glycolysis and ubiquitination assays","pmids":["35896951"],"confidence":"Medium","gaps":["Glycolytic gene targets bound directly not exhaustively mapped"]},{"year":2022,"claim":"Demonstrated OVOL2 binds NF-κB p65 to swap p300 for HDAC1, suppressing GLUT1-driven glucose import, while NF-κB reciprocally degrades OVOL2.","evidence":"Co-IP, luciferase, xenografts, Western, immunostaining","pmids":["35346238"],"confidence":"Medium","gaps":["E3 ligase mediating NF-κB-driven OVOL2 degradation not identified"]},{"year":2022,"claim":"Revealed transcriptional repression of RhoU/RhoJ as the basis for OVOL2-induced mitotic block and reduced invasiveness in anaplastic thyroid cancer.","evidence":"Overexpression, RNA-seq, ChIP-seq, RhoU/RhoJ knockdown, spindle imaging","pmids":["35337349"],"confidence":"Medium","gaps":["Single lab","In vivo relevance not established"]},{"year":2022,"claim":"Established a non-EMT physiological role: OVOL2 is required for adaptive thermogenesis and limits white adipogenesis by blocking C/EBPα target engagement, controlling energy expenditure.","evidence":"ENU hypomorphic (boh) allele, pair-feeding, metabolic cages, adipocyte overexpression, Lepob/ob cross","pmids":["36228616"],"confidence":"High","gaps":["Mechanism of C/EBPα blockade at molecular level not detailed"]},{"year":2022,"claim":"Defined an epigenetic mechanism for epithelial identity maintenance: OVOL2 disrupts RCOR1-LSD1 within the BRAF-HDAC complex to block H3K4me2 demethylation in thymic epithelium.","evidence":"Viable C120Y missense allele, TEC-specific deletion, Co-IP, chromatin accessibility and H3K4me2 assays","pmids":["38012144"],"confidence":"High","gaps":["Whether LSD1 disruption operates at OVOL2's classic EMT targets unknown"]},{"year":2022,"claim":"Distinguished isoform-specific functions, with the repressor-domain Ovol2a regulating EMT genes/pluripotency and Ovol2b lacking the repressor domain activating PGC-specification genes.","evidence":"Splice-variant-specific KO/KI in mouse embryos, transcriptome and direct target analysis","pmids":["35029669"],"confidence":"Medium","gaps":["Mechanism by which Ovol2b activates genes not defined"]},{"year":2024,"claim":"Linked OVOL2 loss to fatty-acid-oxidation-fueled cancer stemness via direct JAK repression and HDAC1 recruitment to STAT3, reducing CPT1A/CPT1B activation.","evidence":"PyVT-Ovol2 KO mice, Co-IP, ChIP/luciferase at JAK promoter, FAO inhibitor, sphere assay","pmids":["38627980"],"confidence":"Medium","gaps":["Single lab","Generality across tumor types not tested"]},{"year":null,"claim":"How OVOL2 toggles between transcriptional repressor and co-activator modes, and how its post-translational modifications (PARylation, ubiquitination) are spatiotemporally coordinated to select context-specific target repertoires, remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unified structural or biochemical model of OVOL2 cofactor switching","Determinants of tissue-specific target selection unknown"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[0,1,11,13,19,23]},{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[0,13,14,19]},{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[4,10,22,25]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[10,28]},{"term_id":"GO:0005654","term_label":"nucleoplasm","supporting_discovery_ids":[4,25]}],"pathway":[{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[0,1,13,19]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[4,9,12,22]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[6,7,9,29]},{"term_id":"R-HSA-4839726","term_label":"Chromatin organization","supporting_discovery_ids":[15,25]},{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[21,24,27]}],"complexes":[],"partners":["ZEB1","TCF4","CTNNB1","HDAC1","HDAC3","NCOR1","ETV2","RELA"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q9BRP0","full_name":"Transcription factor Ovo-like 2","aliases":["Zinc finger protein 339"],"length_aa":275,"mass_kda":30.4,"function":"Zinc-finger transcription repressor factor (PubMed:19700410). Plays a critical role in maintaining the identity of epithelial lineages by suppressing epithelial-to mesenchymal transition (EMT) mainly through the repression of ZEB1, an EMT inducer (By similarity). Positively regulates neuronal differentiation (By similarity). Suppresses cell cycling and terminal differentiation of keratinocytes by directly repressing MYC and NOTCH1 (PubMed:19700410). Important for the correct development of primordial germ cells in embryos (By similarity). Plays dual functions in thermogenesis and adipogenesis to maintain energy balance. Essential for brown/beige adipose tissue-mediated thermogenesis, is necessary for the development of brown adipocytes. In white adipose tissues, limits adipogenesis by blocking CEBPA binding to its transcriptional targets and inhibiting its transcription factor activity (By similarity)","subcellular_location":"Nucleus","url":"https://www.uniprot.org/uniprotkb/Q9BRP0/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/OVOL2","classification":"Not Classified","n_dependent_lines":21,"n_total_lines":1208,"dependency_fraction":0.0173841059602649},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/OVOL2","total_profiled":1310},"omim":[{"mim_id":"616442","title":"OVO-LIKE 3; OVOL3","url":"https://www.omim.org/entry/616442"},{"mim_id":"616441","title":"OVO-LIKE 2; OVOL2","url":"https://www.omim.org/entry/616441"},{"mim_id":"122000","title":"CORNEAL DYSTROPHY, POSTERIOR POLYMORPHOUS, 1; PPCD1","url":"https://www.omim.org/entry/122000"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Nucleoplasm","reliability":"Approved"},{"location":"Cytosol","reliability":"Additional"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"salivary gland","ntpm":6.7},{"tissue":"stomach 1","ntpm":7.4}],"url":"https://www.proteinatlas.org/search/OVOL2"},"hgnc":{"alias_symbol":["bA504H3.3","HOVO2","CHED"],"prev_symbol":["ZNF339","CHED1"]},"alphafold":{"accession":"Q9BRP0","domains":[{"cath_id":"3.30.160","chopping":"110-144","consensus_level":"medium","plddt":75.1349,"start":110,"end":144}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9BRP0","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q9BRP0-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q9BRP0-F1-predicted_aligned_error_v6.png","plddt_mean":60.75},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=OVOL2","jax_strain_url":"https://www.jax.org/strain/search?query=OVOL2"},"sequence":{"accession":"Q9BRP0","fasta_url":"https://rest.uniprot.org/uniprotkb/Q9BRP0.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q9BRP0/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9BRP0"}},"corpus_meta":[{"pmid":"26554584","id":"PMC_26554584","title":"An Ovol2-Zeb1 Mutual Inhibitory Circuit Governs Bidirectional and Multi-step Transition between Epithelial and Mesenchymal States.","date":"2015","source":"PLoS computational biology","url":"https://pubmed.ncbi.nlm.nih.gov/26554584","citation_count":214,"is_preprint":false},{"pmid":"24124593","id":"PMC_24124593","title":"Transcription factors OVOL1 and OVOL2 induce the mesenchymal to epithelial transition in human cancer.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24124593","citation_count":198,"is_preprint":false},{"pmid":"24735879","id":"PMC_24735879","title":"Mammary morphogenesis and regeneration require the inhibition of EMT at terminal end buds by Ovol2 transcriptional repressor.","date":"2014","source":"Developmental cell","url":"https://pubmed.ncbi.nlm.nih.gov/24735879","citation_count":160,"is_preprint":false},{"pmid":"26749309","id":"PMC_26749309","title":"Autosomal-Dominant Corneal Endothelial Dystrophies CHED1 and PPCD1 Are Allelic Disorders Caused by Non-coding Mutations in the Promoter of OVOL2.","date":"2015","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/26749309","citation_count":63,"is_preprint":false},{"pmid":"16423343","id":"PMC_16423343","title":"The mouse Ovol2 gene is required for cranial neural tube development.","date":"2006","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/16423343","citation_count":59,"is_preprint":false},{"pmid":"17049212","id":"PMC_17049212","title":"Strain-dependent perinatal lethality of Ovol1-deficient mice and identification of Ovol2 as a downstream target of Ovol1 in skin epidermis.","date":"2006","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/17049212","citation_count":55,"is_preprint":false},{"pmid":"29721073","id":"PMC_29721073","title":"OVOL2 links stemness and metastasis via fine-tuning epithelial-mesenchymal transition in nasopharyngeal carcinoma.","date":"2018","source":"Theranostics","url":"https://pubmed.ncbi.nlm.nih.gov/29721073","citation_count":54,"is_preprint":false},{"pmid":"26619963","id":"PMC_26619963","title":"OVOL2, an Inhibitor of WNT Signaling, Reduces Invasive Activities of Human and Mouse Cancer Cells and Is Down-regulated in Human Colorectal Tumors.","date":"2015","source":"Gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/26619963","citation_count":50,"is_preprint":false},{"pmid":"19700410","id":"PMC_19700410","title":"Ovol2 suppresses cell cycling and terminal differentiation of keratinocytes by directly repressing c-Myc and Notch1.","date":"2009","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19700410","citation_count":49,"is_preprint":false},{"pmid":"29454536","id":"PMC_29454536","title":"The role of the OVOL1-OVOL2 axis in normal and diseased human skin.","date":"2018","source":"Journal of dermatological science","url":"https://pubmed.ncbi.nlm.nih.gov/29454536","citation_count":45,"is_preprint":false},{"pmid":"12213202","id":"PMC_12213202","title":"Ovol2, a mammalian homolog of Drosophila ovo: gene structure, chromosomal mapping, and aberrant expression in blind-sterile mice.","date":"2002","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/12213202","citation_count":45,"is_preprint":false},{"pmid":"17573777","id":"PMC_17573777","title":"Ovol2/Movo, a homologue of Drosophila ovo, is required for angiogenesis, heart formation and placental development in mice.","date":"2007","source":"Genes to cells : devoted to molecular & cellular mechanisms","url":"https://pubmed.ncbi.nlm.nih.gov/17573777","citation_count":45,"is_preprint":false},{"pmid":"31019211","id":"PMC_31019211","title":"OVOL2 induces mesenchymal-to-epithelial transition in fibroblasts and enhances cell-state reprogramming towards epithelial lineages.","date":"2019","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/31019211","citation_count":36,"is_preprint":false},{"pmid":"30413481","id":"PMC_30413481","title":"An Ovol2-Zeb1 transcriptional circuit regulates epithelial directional migration and proliferation.","date":"2018","source":"EMBO reports","url":"https://pubmed.ncbi.nlm.nih.gov/30413481","citation_count":33,"is_preprint":false},{"pmid":"28455959","id":"PMC_28455959","title":"OVOL2 antagonizes TGF-β signaling to regulate epithelial to mesenchymal transition during mammary tumor metastasis.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/28455959","citation_count":33,"is_preprint":false},{"pmid":"35896951","id":"PMC_35896951","title":"Transcriptional Repression of Aerobic Glycolysis by OVOL2 in Breast Cancer.","date":"2022","source":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/35896951","citation_count":32,"is_preprint":false},{"pmid":"28339425","id":"PMC_28339425","title":"Potential role of the OVOL1-OVOL2 axis and c-Myc in the progression of cutaneous squamous cell carcinoma.","date":"2017","source":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","url":"https://pubmed.ncbi.nlm.nih.gov/28339425","citation_count":32,"is_preprint":false},{"pmid":"27884772","id":"PMC_27884772","title":"Ovol2 gene inhibits the Epithelial-to-Mesenchymal Transition in lung adenocarcinoma by transcriptionally repressing Twist1.","date":"2016","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/27884772","citation_count":30,"is_preprint":false},{"pmid":"29394105","id":"PMC_29394105","title":"Down-regulation of transcription factor OVOL2 contributes to epithelial-mesenchymal transition in a noninvasive type of trophoblast implantation to the maternal endometrium.","date":"2018","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/29394105","citation_count":30,"is_preprint":false},{"pmid":"23319585","id":"PMC_23319585","title":"The zinc finger transcription factor Ovol2 acts downstream of the bone morphogenetic protein pathway to regulate the cell fate decision between neuroectoderm and mesendoderm.","date":"2013","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/23319585","citation_count":29,"is_preprint":false},{"pmid":"25267199","id":"PMC_25267199","title":"OVOL2 is a critical regulator of ER71/ETV2 in generating FLK1+, hematopoietic, and endothelial cells from embryonic stem cells.","date":"2014","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/25267199","citation_count":25,"is_preprint":false},{"pmid":"33989778","id":"PMC_33989778","title":"Dysregulation of the Pdx1/Ovol2/Zeb2 axis in dedifferentiated β-cells triggers the induction of genes associated with epithelial-mesenchymal transition in diabetes.","date":"2021","source":"Molecular metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/33989778","citation_count":25,"is_preprint":false},{"pmid":"26873447","id":"PMC_26873447","title":"Activation of the OVOL1-OVOL2 Axis in the Hair Bulb and in Pilomatricoma.","date":"2016","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/26873447","citation_count":24,"is_preprint":false},{"pmid":"32106476","id":"PMC_32106476","title":"OVOL2-Mediated ZEB1 Downregulation May Prevent Promotion of Actinic Keratosis to Cutaneous Squamous Cell Carcinoma.","date":"2020","source":"Journal of clinical medicine","url":"https://pubmed.ncbi.nlm.nih.gov/32106476","citation_count":24,"is_preprint":false},{"pmid":"29872308","id":"PMC_29872308","title":"Ovol2 induces mesenchymal-epithelial transition via targeting ZEB1 in osteosarcoma.","date":"2018","source":"OncoTargets and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/29872308","citation_count":23,"is_preprint":false},{"pmid":"28046031","id":"PMC_28046031","title":"Confirmation of the OVOL2 Promoter Mutation c.-307T>C in Posterior Polymorphous Corneal Dystrophy 1.","date":"2017","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/28046031","citation_count":19,"is_preprint":false},{"pmid":"31233731","id":"PMC_31233731","title":"Alterations in GRHL2-OVOL2-ZEB1 axis and aberrant activation of Wnt signaling lead to altered gene transcription in posterior polymorphous corneal dystrophy.","date":"2019","source":"Experimental eye research","url":"https://pubmed.ncbi.nlm.nih.gov/31233731","citation_count":16,"is_preprint":false},{"pmid":"31403532","id":"PMC_31403532","title":"Direct Reprogramming Into Corneal Epithelial Cells Using a Transcriptional Network Comprising PAX6, OVOL2, and KLF4.","date":"2019","source":"Cornea","url":"https://pubmed.ncbi.nlm.nih.gov/31403532","citation_count":16,"is_preprint":false},{"pmid":"32244352","id":"PMC_32244352","title":"The Transcription Factor OVOL2 Represses ID2 and Drives Differentiation of Trophoblast Stem Cells and Placental Development in Mice.","date":"2020","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/32244352","citation_count":15,"is_preprint":false},{"pmid":"35337349","id":"PMC_35337349","title":"OVOL2 impairs RHO GTPase signaling to restrain mitosis and aggressiveness of Anaplastic Thyroid Cancer.","date":"2022","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/35337349","citation_count":14,"is_preprint":false},{"pmid":"36228616","id":"PMC_36228616","title":"Obesity caused by an OVOL2 mutation reveals dual roles of OVOL2 in promoting thermogenesis and limiting white adipogenesis.","date":"2022","source":"Cell metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/36228616","citation_count":14,"is_preprint":false},{"pmid":"27729805","id":"PMC_27729805","title":"Expression of Ovol2 is related to epithelial characteristics and shows a favorable clinical outcome in hepatocellular carcinoma.","date":"2016","source":"OncoTargets and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/27729805","citation_count":14,"is_preprint":false},{"pmid":"38627980","id":"PMC_38627980","title":"Loss of OVOL2 in Triple-Negative Breast Cancer Promotes Fatty Acid Oxidation Fueling Stemness Characteristics.","date":"2024","source":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/38627980","citation_count":12,"is_preprint":false},{"pmid":"35346238","id":"PMC_35346238","title":"An NF-κB/OVOL2 circuit regulates glucose import and cell survival in non-small cell lung cancer.","date":"2022","source":"Cell communication and signaling : CCS","url":"https://pubmed.ncbi.nlm.nih.gov/35346238","citation_count":10,"is_preprint":false},{"pmid":"21636736","id":"PMC_21636736","title":"Restricted expression of Ovol2/MOVO in XY body of mouse spermatocytes at the pachytene stage.","date":"2011","source":"Journal of andrology","url":"https://pubmed.ncbi.nlm.nih.gov/21636736","citation_count":10,"is_preprint":false},{"pmid":"35029669","id":"PMC_35029669","title":"Dual role of Ovol2 on the germ cell lineage segregation during gastrulation in mouse embryogenesis.","date":"2022","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/35029669","citation_count":9,"is_preprint":false},{"pmid":"37336658","id":"PMC_37336658","title":"OVOL2: an epithelial lineage determiner with emerging roles in energy homeostasis.","date":"2023","source":"Trends in cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/37336658","citation_count":8,"is_preprint":false},{"pmid":"30542118","id":"PMC_30542118","title":"Poly(ADP-ribosyl)ation of OVOL2 regulates aneuploidy and cell death in cancer cells.","date":"2018","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/30542118","citation_count":8,"is_preprint":false},{"pmid":"34098198","id":"PMC_34098198","title":"OVOL2 attenuates the expression of MAP3K8 to suppress epithelial mesenchymal transition in colorectal cancer.","date":"2021","source":"Pathology, research and practice","url":"https://pubmed.ncbi.nlm.nih.gov/34098198","citation_count":5,"is_preprint":false},{"pmid":"31759386","id":"PMC_31759386","title":"Ovol2, a zinc finger transcription factor, is dispensable for spermatogenesis in mice.","date":"2019","source":"Reproductive biology and endocrinology : RB&E","url":"https://pubmed.ncbi.nlm.nih.gov/31759386","citation_count":5,"is_preprint":false},{"pmid":"38318371","id":"PMC_38318371","title":"OVOL2 induces autophagy-mediated epithelial-mesenchymal transition by the ERK1/2 MAPK signaling in lung adenocarcinoma.","date":"2024","source":"iScience","url":"https://pubmed.ncbi.nlm.nih.gov/38318371","citation_count":4,"is_preprint":false},{"pmid":"34469340","id":"PMC_34469340","title":"c.-61G>A in OVOL2 is a Pathogenic 5' Untranslated Region Variant Causing Posterior Polymorphous Corneal Dystrophy 1.","date":"2022","source":"Cornea","url":"https://pubmed.ncbi.nlm.nih.gov/34469340","citation_count":4,"is_preprint":false},{"pmid":"34984648","id":"PMC_34984648","title":"Altered Epithelial-mesenchymal Plasticity as a Result of Ovol2 Deletion Minimally Impacts the Self-renewal of Adult Mammary Basal Epithelial Cells.","date":"2022","source":"Journal of mammary gland biology and neoplasia","url":"https://pubmed.ncbi.nlm.nih.gov/34984648","citation_count":4,"is_preprint":false},{"pmid":"38012144","id":"PMC_38012144","title":"OVOL2 sustains postnatal thymic epithelial cell identity.","date":"2023","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/38012144","citation_count":3,"is_preprint":false},{"pmid":"35996562","id":"PMC_35996562","title":"Ovo Like Zinc Finger 2 (OVOL2) Suppresses Breast Cancer Stem Cell Traits and Correlates with Immune Cells Infiltration.","date":"2022","source":"Breast cancer (Dove Medical Press)","url":"https://pubmed.ncbi.nlm.nih.gov/35996562","citation_count":2,"is_preprint":false},{"pmid":"36149163","id":"PMC_36149163","title":"Expression of epithelial-mesenchymal transition biomarkers: Discoidin domain receptor 2, Snail-1, and Ovol-2 as predictors of clinical outcome in patients with epithelial ovarian carcinoma.","date":"2022","source":"Journal of cancer research and therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/36149163","citation_count":2,"is_preprint":false},{"pmid":"37971355","id":"PMC_37971355","title":"Ovol2 promoter mutations in mice and human illuminate species-specific phenotypic divergence.","date":"2024","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/37971355","citation_count":1,"is_preprint":false},{"pmid":"40225920","id":"PMC_40225920","title":"Disruption of OVOL2 Distal Regulatory Elements as a Possible Mechanism Implicated in Corneal Endothelial Dystrophy.","date":"2024","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/40225920","citation_count":0,"is_preprint":false},{"pmid":"42252920","id":"PMC_42252920","title":"Sulconazole Suppresses Colorectal Cancer Immune Evasion by Inhibiting Glycolysis to Upregulate OVOL2 PARylation and Induce PANoptosis.","date":"2026","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/42252920","citation_count":0,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":27297,"output_tokens":7811,"usd":0.099528,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":17357,"output_tokens":7084,"usd":0.131942,"stage2_stop_reason":"end_turn"},"total_usd":0.23147,"stage1_batch_id":"msgbatch_013a8chtv3AWyTqv4z4sEF4C","stage2_batch_id":"msgbatch_01AHsuW63vinsvuTgzmQ3n62","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2009,\n      \"finding\": \"OVOL2 directly represses c-Myc and Notch1 transcription in keratinocytes, thereby suppressing transient proliferation and terminal differentiation, respectively. This was established by chromatin immunoprecipitation, luciferase reporter, and functional rescue assays.\",\n      \"method\": \"ChIP, luciferase reporter assay, functional rescue assay, siRNA knockdown in HaCaT cells\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — multiple orthogonal methods (ChIP, luciferase, rescue) in a single focused study establishing direct transcriptional repression\",\n      \"pmids\": [\"19700410\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"OVOL2 acts as a transcriptional repressor that directly represses myriad EMT inducers in mammary epithelial cells. Its absence switches TGF-β response from growth arrest to EMT. Forced expression of the repressor isoform of OVOL2 reprograms metastatic breast cancer cells from mesenchymal to epithelial state.\",\n      \"method\": \"Conditional Ovol2 knockout mice, in vivo mammary morphogenesis assay, forced expression in cancer cells, molecular characterization of TGF-β response\",\n      \"journal\": \"Developmental cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo KO with defined phenotype plus in vitro forced expression rescue, multiple orthogonal experiments\",\n      \"pmids\": [\"24735879\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"OVOL1 and OVOL2 induce mesenchymal-to-epithelial transition (MET) in human cancers via a regulatory feedback loop with EMT-inducing transcription factor ZEB1, and regulate mRNA splicing by inducing ESRP1. Expression of OVOL-TFs in mesenchymal prostate cancer cells attenuates metastatic potential in mouse tumor models.\",\n      \"method\": \"Overexpression in cancer cell lines, mouse prostate tumor models, expression analysis across 917 cancer cell lines\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — in vivo mouse model plus in vitro overexpression, single lab, multiple cancer models\",\n      \"pmids\": [\"24124593\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"OVOL2 and ZEB1 form a mutual inhibitory circuit (double-negative feedback loop). Evidence for direct mutual inhibition was obtained experimentally; this circuit generates multiple intermediate EMT states and modulates bidirectional transitions between epithelial and mesenchymal states.\",\n      \"method\": \"Mathematical modeling integrated with experimental validation; measurement of Ovol2 and Zeb1 expression in intermediate cell states\",\n      \"journal\": \"PLoS computational biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — systems biology approach with experimental validation of mutual inhibition, single lab\",\n      \"pmids\": [\"26554584\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"OVOL2 inhibits WNT signaling by binding TCF4 and β-catenin and facilitating recruitment of histone deacetylase 1 (HDAC1) to the TCF4–β-catenin complex, thereby inhibiting expression of WNT-regulated EMT genes (e.g., SLUG). The OVOL2-containing complex was purified by tandem affinity purification and confirmed by co-immunoprecipitation.\",\n      \"method\": \"Tandem affinity purification, co-immunoprecipitation, luciferase reporter assays, lentiviral overexpression, intestine-specific Ovol2 knockout mice, Apc(min/+) cross\",\n      \"journal\": \"Gastroenterology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — complex purification by TAP/MS confirmed by Co-IP, reporter assays, and in vivo genetic models with defined phenotype\",\n      \"pmids\": [\"26619963\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Non-coding mutations in the OVOL2 proximal promoter cause autosomal-dominant corneal endothelial dystrophies CHED1 and PPCD1. All four mutated OVOL2 promoters showed increased transcriptional activity compared to wild-type in vitro, indicating gain-of-function aberrant OVOL2 expression in corneal endothelium as disease mechanism. OVOL2 is a direct transcriptional repressor of ZEB1.\",\n      \"method\": \"Targeted and whole-genome sequencing, direct promoter sequencing in pedigrees, in vitro luciferase transcriptional activity assays\",\n      \"journal\": \"American journal of human genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — functional promoter assay replicated across four independent mutations, large pedigree-based genetic study with functional validation\",\n      \"pmids\": [\"26749309\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Ovol2 is required for cranial neural tube development, neural crest cell migration and survival, and proper ectodermal patterning in mice. Ovol2 knockout results in lethality by E10.5 with open cranial neural tube, improper Shh expression, and lateral shift of neuroectoderm/surface ectoderm border.\",\n      \"method\": \"Ovol2 gene knockout mice, in situ hybridization, immunostaining, marker expression analysis\",\n      \"journal\": \"Developmental biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — full KO mouse model with multiple defined molecular phenotypes, replicated by another KO study\",\n      \"pmids\": [\"16423343\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Ovol2 is required for extraembryonic and embryonic vascularization and heart formation in mice. Ovol2-deficient mice die at E9.5–10.5 due to vascular and cardiac defects. In an endothelial cell line, siRNA knockdown of Ovol2 inhibited capillary-like network formation on Matrigel.\",\n      \"method\": \"Gene-targeted Ovol2 knockout mice, siRNA knockdown in endothelial cells, Matrigel capillary formation assay\",\n      \"journal\": \"Genes to cells : devoted to molecular & cellular mechanisms\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo KO with defined vascular phenotype plus in vitro functional assay, single lab\",\n      \"pmids\": [\"17573777\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"OVOL2 is a downstream target of OVOL1: Ovol1 represses Ovol2 promoter activity in a DNA binding-dependent manner, and Ovol2 expression is upregulated in Ovol1-deficient epidermis.\",\n      \"method\": \"Ovol1 knockout mouse analysis, promoter repression assay (DNA binding-dependent), qRT-PCR\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — promoter assay plus in vivo mouse model, single lab\",\n      \"pmids\": [\"17049212\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Ovol2 acts downstream of the BMP signaling pathway: BMP4 directly regulates Ovol2 expression through binding of Smad1/5/8 to the second intron of the Ovol2 gene. Ovol2 in turn promotes mesendodermal and inhibits neural differentiation, mediating BMP-directed cell fate decisions between neuroectoderm and mesendoderm.\",\n      \"method\": \"ES cell differentiation assays, Ovol2 knockdown and overexpression, ChIP showing Smad1/5/8 binding to Ovol2 intron 2, chick embryo electroporation\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — ChIP demonstrating direct Smad binding plus functional rescue in ES cells and in vivo chick model, multiple orthogonal methods\",\n      \"pmids\": [\"23319585\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"OVOL2 directly interacts with ER71/ETV2 transcription factor in the nucleus (but not with ETS1 or ETS2). This interaction enhances ER71-mediated activation of the Flk1 promoter and is critical for generation of FLK1+, endothelial, and hematopoietic cells from embryonic stem cells.\",\n      \"method\": \"Co-immunoprecipitation, luciferase reporter assay (Flk1 promoter), shRNA-mediated knockdown, ES cell differentiation assay\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — Co-IP plus functional reporter assay plus shRNA rescue in ES cell differentiation, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"25267199\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"OVOL2 directly represses Twist1 transcription in lung adenocarcinoma cells by binding to the Twist1 promoter, thereby suppressing EMT-associated migration and invasion.\",\n      \"method\": \"Luciferase reporter assay, chromatin immunoprecipitation (ChIP), Transwell and wound healing assays, rescue experiment\",\n      \"journal\": \"Gene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — ChIP plus luciferase reporter confirming direct promoter binding, functional rescue, single lab\",\n      \"pmids\": [\"27884772\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"OVOL2 inhibits TGF-β signaling at multiple levels: it inhibits Smad4 mRNA expression, induces Smad7 mRNA expression, blocks Smad4 binding to target DNA, and interferes with complex formation between Smad4 and Smad2/3, thereby antagonizing TGF-β-induced EMT in mammary tumor cells.\",\n      \"method\": \"Overexpression and knockdown in mammary tumor cell lines, RT-PCR, co-immunoprecipitation, in vivo mouse tumor models\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — multiple mechanistic levels shown by Co-IP and gene expression assays, in vivo validation, single lab\",\n      \"pmids\": [\"28455959\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"OVOL2 directly suppresses ZEB1 transcription in osteosarcoma cells by binding to the ZEB1 promoter, as demonstrated by luciferase reporter assay and ChIP.\",\n      \"method\": \"Luciferase reporter assay, ChIP, overexpression in MG-63 and SW1353 cells, immunohistochemistry in patient OS tissues\",\n      \"journal\": \"OncoTargets and therapy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP plus reporter assay confirming direct promoter binding in two cell lines, single lab\",\n      \"pmids\": [\"29872308\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"OVOL2 is PARylated by PARP1 at Lysine 145, Lysine 176, and Lysine 212 within its C2H2 zinc finger domains. PARylated OVOL2 alters cell morphology, induces lagging chromosomes and aneuploidy, elevates Cyclin E protein stability, and transcriptionally represses Skp2 (E3 ubiquitin ligase of Cyclin E), as mapped by ChIP.\",\n      \"method\": \"Proteomic approach to identify PARP1 substrate, site-specific mutagenesis (K145/176/212A), Co-IP, ChIP mapping of Skp2 promoter binding site, xenograft and MMTV-PyVT transgenic mouse models\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — proteomic identification plus site-directed mutagenesis plus ChIP plus in vivo mouse models, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"30542118\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"OVOL2 overexpression in fibroblasts suppresses fibroblast-associated gene loci (chromatin becomes inaccessible at OVOL2 target loci) and facilitates reprogramming into epithelial lineages cooperatively with KLF4 and TP63. OVOL2 acts as a transcriptional repressor of fibroblast identity genes.\",\n      \"method\": \"Overexpression in dermal fibroblasts, ATAC-seq (chromatin accessibility), motif enrichment analysis, co-expression with KLF4/TP63/HNF1A\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ATAC-seq plus functional reprogramming assay, single lab\",\n      \"pmids\": [\"31019211\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"OVOL2 downregulation in bovine trophoblasts during implantation occurs via the TEAD3/YAP signaling pathway and results in upregulation of ZEB1, SNAI2, and mesenchymal markers. OVOL2 overexpression decreases ZEB1 transcripts and increases E-cadherin in trophoblast cells.\",\n      \"method\": \"Global expression analysis, trophoblast attachment co-culture system, OVOL2 overexpression and knockdown, RT-PCR, Western blot\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — in vitro co-culture system with overexpression/knockdown, mechanistic pathway (TEAD3/YAP) identified, single lab\",\n      \"pmids\": [\"29394105\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Deletion of Ovol2 in mouse skin epithelium impairs directional migration (increased speed but reduced directionality) and proliferation of keratinocytes and bulge hair follicle stem cells. Simultaneous deletion of Zeb1 restores directional migration to Ovol2-deficient cells, placing Zeb1 downstream of Ovol2 in this process. Live imaging and genetic epistasis established these relationships.\",\n      \"method\": \"Conditional Ovol2 KO mice, Ovol2/Zeb1 double KO epistasis, live imaging of wound explants and Bu-HFSCs, wound healing and anagen assays\",\n      \"journal\": \"EMBO reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis with double KO, live imaging, defined cellular phenotypes, in vivo and in vitro convergent evidence\",\n      \"pmids\": [\"30413481\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"OVOL2 overexpression (along with PAX6 and KLF4) directly reprograms human fibroblasts into corneal epithelial cell-like cells. Suppression of OVOL2 in corneal epithelial cells induces qualities consistent with neural lineage cells, indicating OVOL2 maintains corneal epithelial lineage identity.\",\n      \"method\": \"Transcription factor overexpression in human fibroblasts, loss-of-function (OVOL2 knockdown) in corneal epithelial cells\",\n      \"journal\": \"Cornea\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — overexpression and knockdown with defined cell-fate phenotype, single lab\",\n      \"pmids\": [\"31403532\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"OVOL2 directly binds to and represses the ID2 gene locus in trophoblast stem cells, and directly represses ID2 transcriptional activity. OVOL2-driven repression of ID2 promotes TS cell differentiation; overexpression of ID2 alone is sufficient to reinforce the TS cell stem state.\",\n      \"method\": \"ChIP (OVOL2 binding proximal to ID2 gene), ectopic OVOL2 expression in TS cells, Ovol2 KO TS cells, ID2 overexpression rescue assay\",\n      \"journal\": \"Cells\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — ChIP demonstrating direct binding plus functional rescue (ID2 overexpression), KO and overexpression convergent evidence, single lab\",\n      \"pmids\": [\"32244352\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"In pancreatic β-cells, Pdx1 transactivates Ovol2, which in turn represses Zeb2. Loss of Pdx1 reduces OVOL2 protein, triggering Zeb2-mediated mesenchymal reprogramming of β-cells. Loss- and gain-of-function experiments in MIN6 and EndoC-βH1 cell lines established this Pdx1/Ovol2/Zeb2 axis.\",\n      \"method\": \"Bulk and single-cell RNA-seq, loss- and gain-of-function in MIN6 and EndoC-βH1 cells, analysis of T2D mouse and human datasets\",\n      \"journal\": \"Molecular metabolism\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — RNA-seq plus loss/gain-of-function in two cell lines, supported by in vivo mouse data, single lab\",\n      \"pmids\": [\"33989778\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"OVOL2 represses aerobic glycolysis in breast cancer by recruiting NCoR (nuclear receptor co-repressor) and HDAC3 to directly repress expression of glycolytic genes. The tumor suppressor p53 activates OVOL2 by binding MDM2 and inhibiting MDM2-mediated ubiquitination and degradation of OVOL2, establishing a p53/MDM2/OVOL2 axis.\",\n      \"method\": \"In vitro and in vivo overexpression/KO studies, Co-IP for NCoR/HDAC3 interaction, glycolysis assays, ubiquitination assay\",\n      \"journal\": \"Advanced science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP identifying co-repressor complex plus ubiquitination assay, functional assays in vitro and in vivo, single lab\",\n      \"pmids\": [\"35896951\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"OVOL2 directly binds P65 (NF-κB subunit) and inhibits recruitment of P300 while facilitating HDAC1 binding to P65, thereby suppressing NF-κB signaling and GLUT1 translocation/glucose import in NSCLC. Conversely, NF-κB signaling negatively regulates OVOL2 expression via the ubiquitin-proteasome pathway.\",\n      \"method\": \"Co-immunoprecipitation, luciferase assay, xenograft mouse models, Western blot, immunostaining\",\n      \"journal\": \"Cell communication and signaling\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP identifying direct P65 binding plus functional consequence on HDAC1/P300 recruitment, in vivo validation, single lab\",\n      \"pmids\": [\"35346238\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"OVOL2 transcriptionally inhibits RhoU and RhoJ (RHO GTPase pathway members) in anaplastic thyroid cancer cells, causing G2/M cell cycle block, mitotic spindle abnormalities, and reduced invasiveness. Silencing of RhoU alone recapitulated the OVOL2-driven phenotype. OVOL2 new direct target genes were identified by RNA-seq and ChIP-seq.\",\n      \"method\": \"OVOL2 overexpression in ATC cell lines, RNA-seq, ChIP-seq, RhoU/RhoJ knockdown, cell cycle analysis, immunofluorescence of mitotic spindle\",\n      \"journal\": \"Journal of experimental & clinical cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP-seq plus RNA-seq plus rescue by RhoU silencing, single lab\",\n      \"pmids\": [\"35337349\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"OVOL2 is required for thermogenesis in brown/beige adipose tissue and limits white adipogenesis. In white adipose tissue, OVOL2 inhibited adipogenesis by blocking C/EBPα engagement of its transcriptional targets. Identified via random germline mutagenesis (hypomorphic boh allele causing obesity).\",\n      \"method\": \"ENU-mutagenesis hypomorphic mouse allele (boh), pair-feeding experiments, Ovol2 overexpression in adipocytes, cold tolerance tests, Lepob/ob cross\",\n      \"journal\": \"Cell metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo hypomorphic allele with defined metabolic phenotype, overexpression rescue, genetic cross, multiple orthogonal in vivo experiments\",\n      \"pmids\": [\"36228616\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"OVOL2 sustains postnatal thymic epithelial cell (TEC) identity by inhibiting the epigenetic regulatory BRAF-HDAC complex, specifically disrupting RCOR1-LSD1 interaction, which causes inhibition of LSD1-mediated H3K4me2 demethylation, resulting in chromatin accessibility and transcriptional activation of epithelial genes. A missense allele (C120Y) established this mechanism.\",\n      \"method\": \"Viable Ovol2 missense (C120Y) mouse allele, TEC-specific Cre deletion, Co-IP for BRAF-HDAC/RCOR1-LSD1 interaction, chromatin accessibility assays, H3K4me2 demethylation assays\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — Co-IP identifying complex disruption plus chromatin/epigenetic assays plus in vivo mouse model with defined phenotype, multiple orthogonal methods\",\n      \"pmids\": [\"38012144\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"A viable hypomorphic Ovol2 allele in mice (boh) reveals that OVOL2 is required for normal energy expenditure. OVOL2-deficient mice develop obesity with normal food intake but decreased energy expenditure, extreme cold intolerance, and insulin resistance.\",\n      \"method\": \"Random germline mutagenesis, pair-feeding, metabolic cage analysis, body composition measurement\",\n      \"journal\": \"Cell metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo genetic model with multiple metabolic phenotypes, pair-feeding controls, replicated in Lepob/ob cross\",\n      \"pmids\": [\"36228616\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Loss of OVOL2 in triple-negative breast cancer promotes fatty acid oxidation (FAO) fueling stemness. Mechanistically, OVOL2 suppresses STAT3 phosphorylation by directly inhibiting JAK transcription and recruits HDAC1 to STAT3, reducing transcriptional activation of CPT1A and CPT1B (FAO rate-limiting enzymes).\",\n      \"method\": \"OVOL2 KO mice (PyVT-Ovol2 KO), Co-IP for HDAC1-STAT3 interaction, luciferase and ChIP for JAK promoter, FAO inhibitor treatment, sphere-forming assay\",\n      \"journal\": \"Advanced science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP plus ChIP/luciferase identifying direct targets, in vivo KO mouse model, single lab\",\n      \"pmids\": [\"38627980\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Ovol2/MOVO protein localizes to the XY body in spermatocytes at the pachytene stage. In a reporter assay, Ovol2/MOVO repressed histone H1t promoter activity in a spermatogenic cell line, suggesting a role in XY body-associated gene repression during spermatogenesis.\",\n      \"method\": \"Immunohistochemistry with anti-Ovol2 antiserum in mouse testes, luciferase reporter assay (H1t promoter) in GC-2spd cells\",\n      \"journal\": \"Journal of andrology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — direct localization by immunohistochemistry plus reporter assay in spermatogenic cell line, single lab\",\n      \"pmids\": [\"21636736\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Ovol2a splice variant (encoding repressor domain) directly regulates EMT-related genes and induces re-acquisition of pluripotency potential during primordial germ cell (PGC) specification, while Ovol2b splice variant (lacking the repressor domain) directly upregulates genes associated with PGC specification. These functions were established in mouse epiblast during gastrulation.\",\n      \"method\": \"Splice variant-specific knockout/knockin in mouse embryos, transcriptome analysis, direct gene target identification\",\n      \"journal\": \"Development (Cambridge, England)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo splice-variant-specific KO/KI distinguishing isoform functions, single lab\",\n      \"pmids\": [\"35029669\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"OVOL2 inhibits EMT in colorectal cancer cells by blocking the MAP3K8/AKT/NF-κB signaling pathway, identified by cross-referencing ChIP-seq data with RNA-seq differentially expressed genes in OVOL2-overexpressing vs. knockdown cells.\",\n      \"method\": \"RNA-seq, ChIP-seq (GSM1239518), wound-healing and Transwell assays, overexpression and knockdown in HCT116/SW480 cells\",\n      \"journal\": \"Pathology, research and practice\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP-seq plus RNA-seq cross-referencing plus functional assays, single lab\",\n      \"pmids\": [\"34098198\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"In cutaneous squamous cell carcinoma, OVOL1 is an upstream suppressor of OVOL2 and c-Myc: knockdown of OVOL1 using siRNA increased mRNA and protein levels of both c-Myc and OVOL2. Knockdown of OVOL2 did not significantly affect c-Myc or OVOL1 levels.\",\n      \"method\": \"siRNA knockdown of OVOL1 and OVOL2 in A431 SCC cell line, RT-PCR, Western blot, immunohistochemistry in clinical samples\",\n      \"journal\": \"Modern pathology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — siRNA knockdown experiments in one cell line with molecular readout, supported by IHC in clinical samples, single lab\",\n      \"pmids\": [\"28339425\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"OVOL2 is an evolutionarily conserved C2H2 zinc-finger transcriptional repressor that maintains epithelial identity by directly repressing EMT inducers (ZEB1, Twist1, Snail family members) and key cell-cycle/differentiation regulators (c-Myc, Notch1, ID2), operating downstream of BMP/Smad and Wnt/TCF4-β-catenin signaling; it forms direct protein complexes with co-repressors (HDAC1, HDAC3, NCoR) to suppress glycolysis, FAO, and NF-κB-driven glucose import, is subject to PARP1-mediated PARylation and MDM2-mediated ubiquitination that modulate its activity, and controls epithelial lineage identity in diverse tissues (mammary gland, thymus, placenta, adipose, cornea) through both transcriptional repression and epigenetic remodeling (disruption of RCOR1-LSD1-mediated H3K4me2 demethylation).\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"OVOL2 is an evolutionarily conserved C2H2 zinc-finger transcriptional repressor that safeguards epithelial identity and governs developmental cell-fate decisions, principally by directly silencing EMT-inducing transcription factors [#1, #13]. Its central regulatory module is a double-negative feedback circuit with ZEB1: OVOL2 binds and represses the ZEB1 promoter, and the two factors mutually inhibit one another to generate stable epithelial, mesenchymal, and intermediate states [#3, #13]. Beyond ZEB1, OVOL2 directly represses Twist1, c-Myc, Notch1, and ID2, thereby restraining EMT, proliferation, terminal differentiation, and stemness across keratinocytes, lung and breast carcinoma, and trophoblast stem cells [#0, #11, #19]. OVOL2 also antagonizes signaling inputs that drive mesenchymal programs: it binds the TCF4–\\u03b2-catenin complex and recruits HDAC1 to block WNT-driven EMT genes, inhibits TGF-\\u03b2/Smad signaling, and binds NF-\\u03baB p65 to favor HDAC1 over p300 recruitment [#4, #12, #22]. It acts downstream of BMP/Smad and lineage factors such as Pdx1 to direct fate choices between neuroectoderm and mesendoderm and to maintain \\u03b2-cell, corneal, and thymic epithelial identity [#9, #20, #25]. OVOL2 is required in vivo for cranial neural tube closure, vascular and cardiac development, and epithelial morphogenesis, and its activity is tuned post-translationally by PARP1-mediated PARylation within its zinc-finger domains and by p53/MDM2-controlled ubiquitination [#6, #7, #14, #21]. Through co-repressor recruitment (HDAC1, HDAC3, NCoR) and disruption of RCOR1-LSD1-mediated H3K4me2 demethylation, OVOL2 enforces transcriptional and epigenetic repression that also restrains aerobic glycolysis and fatty-acid oxidation and supports adaptive thermogenesis [#21, #25, #27, #24]. In humans, non-coding gain-of-function mutations in the OVOL2 proximal promoter cause the autosomal-dominant corneal endothelial dystrophies CHED1 and PPCD1 [#5].\",\n  \"teleology\": [\n    {\n      \"year\": 2006,\n      \"claim\": \"Established that OVOL2 is essential in vivo before any molecular targets were known, defining its developmental requirement in neural tube, ectodermal patterning, and vascular/cardiac formation.\",\n      \"evidence\": \"Ovol2 knockout mice with in situ hybridization and marker analysis; endothelial siRNA and Matrigel assay\",\n      \"pmids\": [\"16423343\", \"17573777\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct transcriptional targets driving these phenotypes not yet identified\", \"Did not establish whether defects are cell-autonomous\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Placed OVOL2 within an OVOL regulatory hierarchy by showing OVOL1 represses the Ovol2 promoter in a DNA-binding-dependent manner.\",\n      \"evidence\": \"Ovol1 knockout epidermis analysis, promoter repression assay, qRT-PCR\",\n      \"pmids\": [\"17049212\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab\", \"Functional consequence of OVOL1→OVOL2 repression in vivo not resolved\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Identified the first direct OVOL2 target genes (c-Myc, Notch1), establishing it as a sequence-specific transcriptional repressor coordinating proliferation and differentiation in keratinocytes.\",\n      \"evidence\": \"ChIP, luciferase reporter, and functional rescue with siRNA knockdown in HaCaT cells\",\n      \"pmids\": [\"19700410\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Co-repressor machinery not defined\", \"Limited to keratinocyte context\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Defined OVOL2 as a downstream effector of BMP/Smad signaling that biases neuroectoderm-versus-mesendoderm fate decisions.\",\n      \"evidence\": \"ES cell differentiation, ChIP of Smad1/5/8 at Ovol2 intron 2, chick embryo electroporation\",\n      \"pmids\": [\"23319585\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Downstream targets mediating mesendoderm induction not fully mapped\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Generalized OVOL2 function to cancer by showing OVOL-TFs drive MET via a ZEB1 feedback loop and induce ESRP1-dependent splicing, attenuating metastasis.\",\n      \"evidence\": \"Overexpression in cancer lines, mouse prostate tumor models, expression survey across 917 lines\",\n      \"pmids\": [\"24124593\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Directness of ZEB1 feedback established later\", \"Single lab\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Demonstrated in vivo that OVOL2 loss converts the TGF-\\u03b2 response from growth arrest to EMT, and that the repressor isoform reprograms metastatic cells back to epithelial state.\",\n      \"evidence\": \"Conditional Ovol2 knockout mice, mammary morphogenesis, forced expression rescue in cancer cells\",\n      \"pmids\": [\"24735879\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full repertoire of repressed EMT inducers not enumerated\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Revealed an activating (non-repressive) mode of OVOL2 action through direct nuclear interaction with ER71/ETV2 to drive endothelial/hematopoietic specification.\",\n      \"evidence\": \"Co-IP, Flk1 promoter luciferase, shRNA knockdown in ES cell differentiation\",\n      \"pmids\": [\"25267199\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How OVOL2 switches between repressor and co-activator roles unknown\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Mechanistically linked OVOL2 to WNT antagonism by showing it binds TCF4/\\u03b2-catenin and recruits HDAC1 to repress WNT-EMT genes, with in vivo tumor relevance.\",\n      \"evidence\": \"Tandem affinity purification, Co-IP, luciferase, intestine-specific KO and Apc(min/+) cross\",\n      \"pmids\": [\"26619963\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether HDAC1 recruitment is universal across OVOL2 targets not established\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Formalized the OVOL2–ZEB1 double-negative feedback loop as the bistable switch generating intermediate EMT states.\",\n      \"evidence\": \"Mathematical modeling with experimental measurement of Ovol2/Zeb1 in intermediate states\",\n      \"pmids\": [\"26554584\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Systems-level inference; in vivo proof of intermediate-state control limited\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Connected OVOL2 to human disease, showing promoter mutations cause CHED1/PPCD1 via gain-of-function aberrant expression in corneal endothelium.\",\n      \"evidence\": \"Pedigree sequencing plus in vitro promoter luciferase activity across four mutations\",\n      \"pmids\": [\"26749309\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo demonstration of corneal endothelial dysregulation by mutant promoters not shown\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Extended the direct repressor target set to Twist1, broadening OVOL2's EMT-suppressive reach to lung adenocarcinoma.\",\n      \"evidence\": \"Luciferase, ChIP, Transwell/wound healing, rescue in lung cancer cells\",\n      \"pmids\": [\"27884772\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab\", \"In vivo confirmation absent\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Showed OVOL2 antagonizes TGF-\\u03b2 at multiple nodes (Smad4 suppression, Smad7 induction, blocking Smad4 DNA binding and Smad2/3 complex formation).\",\n      \"evidence\": \"Overexpression/knockdown in mammary tumor cells, RT-PCR, Co-IP, in vivo tumor models\",\n      \"pmids\": [\"28455959\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether effects are direct vs. secondary to EMT reversal not fully separated\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Reinforced the OVOL1→OVOL2/c-Myc hierarchy in squamous carcinoma, placing OVOL2 downstream of OVOL1.\",\n      \"evidence\": \"siRNA knockdown in A431 cells, RT-PCR, Western, IHC in clinical samples\",\n      \"pmids\": [\"28339425\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single cell line\", \"Directionality of OVOL2 effects on c-Myc not resolved here\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Uncovered post-translational control: PARP1 PARylates OVOL2 within its zinc fingers, altering its repression of Skp2 and driving chromosomal instability.\",\n      \"evidence\": \"Proteomics, site-directed mutagenesis (K145/176/212A), Co-IP, ChIP, xenograft and MMTV-PyVT models\",\n      \"pmids\": [\"30542118\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Stimuli triggering PARylation in vivo not defined\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Established OVOL2 as an epigenetic repressor of fibroblast identity capable of cooperating with KLF4/TP63 to reprogram cells toward epithelial lineages.\",\n      \"evidence\": \"Overexpression in dermal fibroblasts, ATAC-seq, motif enrichment\",\n      \"pmids\": [\"31019211\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Co-repressor mediating chromatin closure not identified in this study\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Defined a ZEB1-dependent cellular mechanism: OVOL2 controls directional keratinocyte/stem-cell migration via repression of Zeb1, shown by genetic epistasis.\",\n      \"evidence\": \"Conditional and Ovol2/Zeb1 double KO mice, live imaging, wound-healing and anagen assays\",\n      \"pmids\": [\"30413481\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular link between ZEB1 and directional cytoskeletal control not detailed\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Implicated TEAD3/YAP-driven OVOL2 downregulation in trophoblast EMT during implantation, situating OVOL2 in placental epithelial control.\",\n      \"evidence\": \"Trophoblast co-culture, OVOL2 overexpression/knockdown, RT-PCR, Western\",\n      \"pmids\": [\"29394105\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct OVOL2 promoter occupancy at ZEB1/SNAI2 in trophoblast not shown\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Showed OVOL2 maintains corneal epithelial lineage identity, with loss producing neural-like fate, and enabling fibroblast-to-corneal-epithelial reprogramming.\",\n      \"evidence\": \"TF overexpression in human fibroblasts and OVOL2 knockdown in corneal epithelial cells\",\n      \"pmids\": [\"31403532\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct target genes in cornea not mapped\", \"Single lab\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Identified ID2 as a direct OVOL2 target whose repression promotes trophoblast stem-cell differentiation.\",\n      \"evidence\": \"ChIP, ectopic OVOL2 and Ovol2 KO in TS cells, ID2 overexpression rescue\",\n      \"pmids\": [\"32244352\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Co-repressor recruitment at ID2 locus not characterized\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Defined a Pdx1/Ovol2/Zeb2 axis preserving \\u03b2-cell identity, where OVOL2 loss permits Zeb2-driven mesenchymal reprogramming relevant to diabetes.\",\n      \"evidence\": \"Bulk and scRNA-seq, loss/gain-of-function in MIN6 and EndoC-\\u03b2H1, T2D datasets\",\n      \"pmids\": [\"33989778\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct OVOL2 binding at Zeb2 promoter not shown here\", \"Single lab\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Linked OVOL2 to MAP3K8/AKT/NF-\\u03baB suppression as a mechanism of EMT inhibition in colorectal cancer.\",\n      \"evidence\": \"RNA-seq and ChIP-seq cross-referencing, wound-healing/Transwell, overexpression/knockdown\",\n      \"pmids\": [\"34098198\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct vs. indirect regulation of MAP3K8 not fully resolved\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Showed OVOL2 represses aerobic glycolysis via NCoR/HDAC3 recruitment, and is itself stabilized by p53 through inhibition of MDM2-mediated degradation.\",\n      \"evidence\": \"Overexpression/KO, Co-IP for NCoR/HDAC3, glycolysis and ubiquitination assays\",\n      \"pmids\": [\"35896951\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Glycolytic gene targets bound directly not exhaustively mapped\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Demonstrated OVOL2 binds NF-\\u03baB p65 to swap p300 for HDAC1, suppressing GLUT1-driven glucose import, while NF-\\u03baB reciprocally degrades OVOL2.\",\n      \"evidence\": \"Co-IP, luciferase, xenografts, Western, immunostaining\",\n      \"pmids\": [\"35346238\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"E3 ligase mediating NF-\\u03baB-driven OVOL2 degradation not identified\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Revealed transcriptional repression of RhoU/RhoJ as the basis for OVOL2-induced mitotic block and reduced invasiveness in anaplastic thyroid cancer.\",\n      \"evidence\": \"Overexpression, RNA-seq, ChIP-seq, RhoU/RhoJ knockdown, spindle imaging\",\n      \"pmids\": [\"35337349\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab\", \"In vivo relevance not established\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Established a non-EMT physiological role: OVOL2 is required for adaptive thermogenesis and limits white adipogenesis by blocking C/EBP\\u03b1 target engagement, controlling energy expenditure.\",\n      \"evidence\": \"ENU hypomorphic (boh) allele, pair-feeding, metabolic cages, adipocyte overexpression, Lepob/ob cross\",\n      \"pmids\": [\"36228616\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of C/EBP\\u03b1 blockade at molecular level not detailed\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Defined an epigenetic mechanism for epithelial identity maintenance: OVOL2 disrupts RCOR1-LSD1 within the BRAF-HDAC complex to block H3K4me2 demethylation in thymic epithelium.\",\n      \"evidence\": \"Viable C120Y missense allele, TEC-specific deletion, Co-IP, chromatin accessibility and H3K4me2 assays\",\n      \"pmids\": [\"38012144\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether LSD1 disruption operates at OVOL2's classic EMT targets unknown\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Distinguished isoform-specific functions, with the repressor-domain Ovol2a regulating EMT genes/pluripotency and Ovol2b lacking the repressor domain activating PGC-specification genes.\",\n      \"evidence\": \"Splice-variant-specific KO/KI in mouse embryos, transcriptome and direct target analysis\",\n      \"pmids\": [\"35029669\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism by which Ovol2b activates genes not defined\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Linked OVOL2 loss to fatty-acid-oxidation-fueled cancer stemness via direct JAK repression and HDAC1 recruitment to STAT3, reducing CPT1A/CPT1B activation.\",\n      \"evidence\": \"PyVT-Ovol2 KO mice, Co-IP, ChIP/luciferase at JAK promoter, FAO inhibitor, sphere assay\",\n      \"pmids\": [\"38627980\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab\", \"Generality across tumor types not tested\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How OVOL2 toggles between transcriptional repressor and co-activator modes, and how its post-translational modifications (PARylation, ubiquitination) are spatiotemporally coordinated to select context-specific target repertoires, remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unified structural or biochemical model of OVOL2 cofactor switching\", \"Determinants of tissue-specific target selection unknown\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [0, 1, 11, 13, 19, 23]},\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [0, 13, 14, 19]},\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [4, 10, 22, 25]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [10, 28]},\n      {\"term_id\": \"GO:0005654\", \"supporting_discovery_ids\": [4, 25]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [0, 1, 13, 19]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [4, 9, 12, 22]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [6, 7, 9, 29]},\n      {\"term_id\": \"R-HSA-4839726\", \"supporting_discovery_ids\": [15, 25]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [21, 24, 27]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"ZEB1\", \"TCF4\", \"CTNNB1\", \"HDAC1\", \"HDAC3\", \"NCOR1\", \"ETV2\", \"RELA\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":8,"faith_total":8,"faith_pct":100.0}}